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Rationale: Smoking effects on physiological and gross pathology in chronic obstructive 
  pulmonary disease (COPD) are relatively well described. However, there is little known in 
COPD about the detailed interrelationships between lung function and inflammatory profiles 
in different airway compartments from the same individual and whether airway inflammation 
in these different compartments differs in ex- and current smokers with established COPD.
Objectives: We compared sputum, bronchoalveolar (BAL), and airway wall inflammatory 
profiles in current versus ex-smokers and related this to smoking intensity and lung function in 
17 current and 17 ex-smokers with mild to moderate COPD.
Results: Current smokers had more sputum mast cells (% differential and absolute numbers), 
whereas ex-smokers had increased sputum neutrophils. In BAL, there was a significant increase 
in eosinophils in current smokers, but ex-smokers had significantly increased neutrophils, 
lymphocytes, and epithelial cells. There were no cell profile differences observed in airway 
biopsies between current and ex-smokers and there were no correlations between the individual 
inflammatory cell populations in any of the airway compartments. In current smokers only, 
smoking intensity was negatively correlated with lung function, and associated with a reduction 
in overall cellularity of both sputum and BAL.
Conclusion: Airway inflammation persists in ex-smokers with COPD, but differs from COPD 
current smokers. The impact of smoking appears to vary in different airway compartments and 
any direct relationships between cellularity and lung function tended to be negative, ie, worse 
lung function indicated the presence of fewer cells.
Keywords: current smokers, ex-smokers, airway cellularity, sputum, BAL, endobronchial 
biopsies
Chronic obstructive pulmonary disease (COPD) is defined as slowly progressive 
airflow obstruction that does not exhibit appreciable variability over days or even 
several months.1 Its predominant cause is cigarette smoking which induces airway 
inflammation and remodeling, with resultant fixed airflow obstruction.2
The gross cellular pathology in the airways in COPD is fairly well described, with an 
increase in airway wall macrophages and CD8 lymphocytes as well as the   development 
of B-cell follicles especially in small airways in severe disease.3,4 In sputum, there is 
classically a neutrophil predominance with a variable degree of eosinophilia,5–7 and 
in BAL there is macrophage predominance, and variably, increased neutrophils.8,9 
Interleukin-8 has been reported to be increased in at least some COPD patients in 
sputum and bronchoalveolar lavage (BAL) samples,10 with cell profiles probably 
reflecting its role as a potent chemoattractant for neutrophils, primed eosinophils, and 
CD4+ and CD8+ T lymphocytes.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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Smoking cessation improves respiratory symptoms 
and may ameliorate excessive decline in lung function in 
COPD.11–13 However, there are few data on the effects of 
smoking cessation on airway inflammation, and the limited 
studies available have shown contradictory results.14 There is 
also little information on the inflammatory profile within the 
airways of ex-smokers with established COPD. Moreover, 
most studies in COPD have been focused on single modali-
ties of airway sampling ie, induced sputum, BAL, or airway 
biopsies and the “established” gross cellular picture outlined 
has been built up from a patchwork of studies. There are 
no studies that we are aware of in which the inflammatory 
profiles in these different “compartments” have been directly 
compared in the same individual, to determine whether the 
pathological effects of smoking and effects of smoking ces-
sation are consistent throughout the airways.
We have therefore undertaken a comprehensive analysis 
of cellular airway inflammation in COPD, both in current 
and ex-smokers. We combined sputum, BAL, and   airway 
  endobronchial biopsy analyses to determine whether 
  differences in lung function and smoking status were   associated 
with particular airway inflammatory cell profiles, whether 
inflammatory changes were similar throughout different airway 
compartments, and whether there was an obvious relationship 
between cellular inflammation and physiological decline.
Materials and methods
Participants
We recruited 17 current and 17 ex-smokers with COPD to 
form our study sample. Ex-smokers were defined as having 
ceased smoking for at least 6 months. COPD was diagnosed 
according to the GOLD criteria.1 Participants were allowed 
to have any degree of BDR following inhalation of 200 µg 
salbutamol, but no history of asthma as confirmed by two 
physicians independently. Smoking intensity was defined both 
as pack-years, and number of cigarettes smoked on average per 
day when smoking, regardless of years of smoking history. All 
participants were in a stable condition at the time of the study 
and free from acute exacerbations of symptoms and/or from 
upper respiratory tract infections for at least one month preced-
ing the study. Participants did not have any active concurrent 
medical problems and/or a clinical history of allergic diseases 
(eg, rhinitis). Atopic status was assessed by skin prick testing to 
a panel of seven common aeroallergens and a positive response 
was defined by a weal diameter of $3 mm. Participants had 
not used corticosteroids in any form in the last three months 
or long acting bronchodilators in the past 4 weeks.
Pulmonary function tests were performed for all   participants 
according to ATS standards.15 BDR was assessed by 
remeasuring spirometry in all participants 20 minutes after 
the inhalation of 200 µg of salbutamol from a Metered Dose 
Inhaler. Gas transfer factor was measured by the single 
breath carbon monoxide method,16 and lung volumes were 
measured in a body plethysmograph post bronchodilator. 
  Carboxyhemoglobin levels were measured during lung   function 
testing and reviewed to confirm the nonsmoking status of the 
ex-smokers.
sputum, BAL, and biopsy sampling  
and processing procedures
Sputum induction was performed with hypertonic saline inha-
lation, following well established methods.17,18 Sputum plugs 
free of salivary contamination were selected and processed 
according to an adaptation of the method used by Pin et al.17 
BAL and endobronchial biopsies were obtained and processed 
as described previously.19,20 Briefly, participants were pre-
medicated with nebulized (5 mg) and sedation was achieved 
with intravenous administration of midazolam (3–10 mg) and 
fentanyl (25–100 µg). Lignocaine (4%) was applied topically 
to the nose, pharynx, and larynx, and 2% lignocaine was 
admistered below the cords. Participants were monitored by 
pulse oximerty and administered oxygen throughout the pro-
cedure. Bronchoalveolar lavage was performed to yield three 
60 mL aliquots from the right middle lobe using a standard 
protocol. Total cell counts were determined on unfiltered 
BALF using a Neubauer hemocytometer and cytocentrifuge 
preparations were stained with toluidine blue and Diff-Quik® 
(American Scientific, McGaw Park, IL, USA) to allow iden-
tification and determination of mast cells and BALF absolute 
and differential cell counts, respectively.
Endobronchial biopsies were then taken from sub-
segmental cariane of the right lower lobe of each patient, 
using alligator forceps (FB-15C; Olympus, Toyko, Japan). 
A maximum of eight biopsies were obtained at each fiberoptic 
bronchoscopy.
Differential cell counts were performed on at least 500 cells 
per slide across the middle band of the   cytocentrifuge spot,20,21 
under 100x magnification using an oil-immersion lens. For 
mast cells, 2,500–5,000 total cells (depending on cytospot 
density) were enumerated by presence of   metachromasia. 
All counting was in duplicate and double blind. Results were 
averaged and expressed as both a percentage and absolute 
count for each cell type.20
Interleukin (IL)-8 concentration in cell-free supernatants of 
sputum and BAL was measured using a four-layer quantitative 
chemiluminescence “sandwich” enzyme linked   immunosorbent 
assay (ELISA), according to the   manufacturer’s instructions 
(R&D systems Inc., Minneapolis, USA).International Journal of Chronic Obstructive Pulmonary Disease 2010:5
Table 2 Lung function in COPD current and ex-smokers
Current smokers 
(n = 17)
Ex-smokers 
(n = 17)
Post BD Fer 57.4 (7.7) 56.4 (9.4)
Pre BD FeV1 (L) 2.0 (0.4) 2.1 (0.4)
Pre BD FeV1, % predicted 71.1 (14.1) 73.4 (14.2)
Post BD FeV1(L) 2.2 (0.4) 2.3 (0.5)
Post BD FeV1, % predicted 78.4 (11.7) 80.7 (15.5)
BDr, % predicted 7.4 (4.8) 7.2 (4.0)
Pre BD FVC (L) 3.5 (0.7) 3.8 (0.9)
Pre BD FVC, % predicted 101.4 (16.1) 108.3 (16.6)
Post BD FVC (L) 3.9 (0.8) 4.1 (0.9)
Post BD FVC, % predicted 111.8 (15.2) 115.9 (16.2)
FVC change, % baseline 10.9 (9.8) 7.3 (7.2)
KCO, % predicted 75.7 (17.9) 66.7 (16.1)
TLC, % predicted 110.4 (9.3) 113.0 (19.6)
rV, % predicted 129.9 (28.3) 123.4 (40.5)
Data are presented as Mean (sD); BD = bronchodilator; Fer = ratio of FeV1 to FVC.
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For staining of cell populations within endobronchial 
biopsies, a chain polymer technology system (Envision 
Plus™, Dakocytomation) was employed.22 Monoclonal anti-
bodies used were anti-neutrophil elastase (Dako, Glostrup, 
Denmark), anti-CD68 (Dako), anti-tryptase A (Dako), anti-
EG1, anti-EG2 (Pharmacia Diagnostics, Uppsala, Sweden), 
anti-CD4, and anti-CD8 (Dako), as well as a negative isotype 
control. Cells were quantified in the subepithelial lamina 
propria up to a depth of 150 µm, excluding vessels, mucosal 
glands, and smooth muscle by light microscopy, by a single 
experienced observer, using an image analyzer (Image Pro 
Plus 4.5, USA). Two quality slides from one of the best tissue 
blocks from each participant were coded and scored blind. 
These scores were averaged for each cell type per individual. 
Results were expressed as the number of positive cells per 
millimeter of epithelial basement membrane.19
statistics
Statistical analysis was performed using SPSS (Version 12.0.1 
for Windows, USA). For two group comparisons, t tests, and 
Mann–Whitney and chi-square tests were used for paramet-
ric and nonparametric data respectively. For correlations, 
Pearson’s test and Spearman’s test were used for parametric 
and nonparametric data, respectively. Data were expressed 
as mean ± standard deviation if parametric, and as median 
and interquartile range if nonparametric. We have previously 
demonstrated in endobronchial biopsies and BAL studies that 
around 15 participants per group is an optimal number.23,24 
Preliminary repeatability data for COPD airway samples were 
similar, indicating that the power versus participant number 
plot flattened markedly beyond this number of particpants 
with little extra gain in power with larger numbers.
Results
sample demographics  
and clinical characteristics
Participants’ demographics and clinical characteristics are 
listed in Table 1. There were no statistical differences in 
regard to age, sex, and atopic status between the two COPD 
groups examined. Although the ex-smokers had a higher 
mean pack year smoking history, the variability within groups 
was large and the difference was not significant.
Lung function
No significant differences were found in any of the lung 
function indices (Table 2). The mean % BDR predicted was 
7.4 and 7.2 in current and ex-smokers (ns). Among current 
smokers there were six participants (35%) with BDR $ 10% 
(given as % of predicted) and in ex-smokers there were four 
(23.5% in the group; not significantly different between 
groups according to the results of a chi-square test).
Inflammatory cell profiles and IL-8 levels
In sputum, current smokers with COPD had significantly 
increased absolute numbers of mast cells compared to 
ex-smokers, who in contrast demonstrated significantly 
increased absolute numbers and percentage differential 
counts of neutrophils (Table 3). In BAL, current smokers 
demonstrated a significant increase in absolute numbers 
and percentage differential counts of eosinophils compared 
to ex-smokers, who in turn exhibited overall decreased total 
cell counts, but with associated increases in lymphocyte, 
neutrophil, and epithelial differential cell percentages as well 
as a trend toward increased IL-8 levels (P = 0.06) (Table 4). In 
contrast, biopsy cellular profiles were very similar (Table 5) 
between current and ex-smokers.
Correlations (Tables 6–8)
There were few significant correlations between smoking 
intensities, airway inflammatory cells, and lung function, 
although there was a significant negative relationship 
Table 1 Participant demographics and clinical characteristics
COPD
Current smokers 
n = 17
Ex-smokers   
n = 17
Age, year 58.9 (7.2) 62.1 (4.5)
gender, M/F 10/7 11/6
smoking pack-years 47.9 (16.8) 60.4 (41.7)
Atopy,† no. of 
participants
4/17 3/17
Data are expressed as Mean (sD). †Atopy means positive results to one or more 
allergens as demonstrated by skin prick tests.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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between smoking intensity and lung function in current 
smokers as perhaps might be expected, ie, more smoking 
was associated with poorer lung function, but this relation-
ship was not seen in the ex-smokers.
In current smokers there was a weak relationship between 
smoking intensity and total cell counts, but this was in a 
negative direction and only in BAL samples ie, more smoking 
was related to fewer total cells in BAL. In ex-smokers, some 
relationships were seen in sputum, BAL, and biopsy between 
smoking intensity and cell counts – but again, these were 
mainly negative (for lymphocytes, mast cells and epithelial 
cells), although positive for macrophages; there was little 
consistency between airway compartment types. In general, 
therefore, more total cells in sputum and BAL tended to be 
associated across the board with better lung function. In 
airway biopsies, higher cell numbers were similarly asso-
ciated with better lung function. For current smokers, the 
strongest such relationships were for neutrophils and CD4 
lymphocytes, and for ex-smokers for CD4 lymphocytes and 
mast cells.
Cell profiles in sputum, BAL, and airway biopsies were 
statistically unrelated to each other in either current or 
ex-smokers with COPD.
Discussion
Our aim in this cross-sectional study was to investigate 
in detail, using different airway compartment sampling 
techniques, the differences between airway inflammatory 
Table 3 sputum cellularity and cytokines
Current 
smokers 
(n = 17)
Ex-smokers 
(n = 15)
Significance
TCC, 104/mL 395  
(250–624)
700  
(197–981)
P = 0.1
Macrophages,  
104/mL
119  
(44–244)
139  
(52–213)
ns
Macrophages % 33.4 
(20.5–58.4)
25.0 
(11.3–35.7)
P = 0.07
neutrophils, 
104/mL
216  
(90–320)
485  
(83–694)
P , 0.05
neutrophils % 57.3  
(29.3–64.5)
70.1  
(48.7–80.0)
P , 0.05
Lymphocytes,  
104/mL
17 (4–47) 33 (10–65) P = 0.06
Lymphocytes % 4.2 (1.9–10.4) 5.1 (4.3–8.8) ns
eosinophils,  
104/mL
6 (4–18) 7 (4–29) ns
eosinophils % 1.9 (0.8–4.6) 1.9 (1.0–4.7) ns
Mast cells,  
107/mL
24 (0–133) 0 (0–630)* P , 0.05
Mast cells/ 
105 cells 
10 (0–34) 0 (0–64) ns
epithelial cells,  
104/mL
0 (0–2.7) 0 (0–2.8) ns
epithelial cells % 0 (0–0.8) 0 (0–0.6) ns
IL-8 ng/mL 4.9 (3.0–7.1) 6.3 (3.9–8.5) ns
Data are presented as Median (interquartile ranges).
Table 4 BAL cellularity and cytokines
Current 
smokers 
(n = 17)
Ex-smokers 
(n = 17)
Significance
TCC, 103/mL 318 (173–429) 154 (96–193) P , 0.01
TCC, numbers, 105 169 (84–396) 74 (40–113) P , 0.01
Macrophages,  
103/mL
234 (161–357) 75 (37–127) P , 0.01
Macrophages % 85.6 
(73.9–91.7)
72.1 
(50.8–86.4)
P , 0.05
Lymphocytes,  
103/mL
15.0 (11–28) 13.0 (7–34) ns
Lymphocytes % 5.1 (3.1–9.8) 12.0 (5.2–26.5) P , 0.05
neutrophils,  
103/mL
6.0 (1–17) 8 (2–19) ns
neutrophils % 2.2 (1.0–5.6) 4.9 (2.4–10.2) P , 0.05
eosinophils,  
103/mL
3.0 (1.0–6.0) 1.0 (0.1–2) P , 0.01
eosinophils % 0.8 (0.5–4.2) 0.5 (0.1–1.4) P , 0.05
Mast cells,  
103/mL
0.2 (0–0.4) 0. 1(0–0.2) ns
Mast cells % 0.1 (0–0.2) 0.1 (0–0.2) ns
epithelial cells,  
103/mL
3.0 (1–7) 8 (2–12) ns
epithelial cells % 1.0 (0.4–3.6) 5 (2–10.5) P , 0.05
IL-8, pg/mL 48.6  
(11.3–82.6)
85.8  
(46.5–131.5)
P = 0.06
Data are presented as Median (interquartile ranges).
Table 5 Biopsy cellularity in COPD
Current 
smokers 
(n = 17)
Ex-smokers 
(n = 17)
Significance
neutrophil 
elastase+
Cells/mm 7.6 
(2.3–16.2)
10.3 
(6.9–16.7)
ns
eg1+ Cells/mm 4.8 
(2.4–10.3)
9.8 
(3.2–13.2)
ns
eg2+ Cells/mm 3.7 
(1.1–11.5)
9.5 
(1.6–15.0)
ns
Mast cell 
tryptase+
Cells/mm 11.6 
(9.6–14.0)
11.2 
(9.5–14.8)
ns
CD4+ Cells/mm 7.3 
(4.2–11.7)
6.8 
(2.7–15.1)
ns
CD8+ Cells/mm 29.3 
(24.3–34.9)
30.2 
(11.4–36.0)
ns
CD4+/ 
CD8+
Cells/mm 0.3 
(0.2–0.5)
0.4 
(0.1–0.6)
ns
CD68+ Cells/mm 22.4 
(14.0–28.1)
19.6 
(12.9–29.8)
ns
Data are presented as Median (interquartile ranges); Cells/mm = cells per mm of 
basement membrane length to a depth of 150 µm in the lamina propria.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
331
Smoking history, inflammation, and lung function in COPD
profiles in current and ex-smokers with established COPD 
and to explore the relationship between airway   inflammation, 
smoking intensity, and lung function. Current smokers had 
an increase in sputum mast cell and BAL eosinophil num-
bers compared to ex-smokers. In contrast, ex-smokers with 
COPD had higher total cell counts and absolute neutrophil 
numbers in sputum, but not in BAL or biopsies compared to 
current smokers. In BAL there was an increase in the relative 
proportions (percentage) of neutrophils, lymphocytes, and 
epithelial cells in ex- versus current smokers and a trend for 
BAL IL-8 levels to be higher in ex-smokers, consistent with 
the higher percentage of neutrophils in BAL. Inflammatory 
cell profiles in the different airway compartments sampled 
appeared to be unrelated. It is quite obvious that the picture 
that can be obtained will vary considerably depending on 
sampling modality used, which explains why the results 
gained in previous reports have varied so much.
Our study results demonstrate that airway inflammation 
persists in COPD ex-smokers but that the cell patterns differ 
compared to current smokers, especially in sputum and BAL. 
The picture in airway biopsies, on the other hand, is similar in 
current and ex-smoker COPD patients, suggesting that once 
COPD is established, trafficking of cells through the airway 
wall into the lumen may be what is different, which may 
reflect remodeling changes and perhaps changes in vascula-
ture, but this cannot be addressed by a cross-sectional study 
and needs-specific prospective study. Notably, for inflam-
matory cell profiles in general, more historical smoking and 
poorer lung function were both associated with less marked 
inflammation, which may imply that cellular inflammation 
is most prominent in milder physiological disease, and that 
later, with more significant physiological abnormality, airway 
remodeling, and perhaps a reduced ability of cells to migrate 
becomes the more predominant pathological process, but this 
also needs prospective study of both airway remodeling and 
cell infiltration after smoking cessation.
Caution obviously needs to be exercised when attributing 
cause and effect relationships from cross-sectional studies 
such as ours, but on the other hand, longitudinal smoking-
cessation studies in COPD needing several years to complete 
are unfortunately difficult to recruit for and undertake. From 
our experience, the majority of recruits with COPD to such 
studies cannot stop smoking at all, or if they manage to quit, it 
is for only such a short time as to make any study of changes 
in airway pathology unfruitful (unpublished data and personal 
observation). Therefore, inferences from cross-sectional 
studies such as the current one are necessary and important 
in trying to gain better understanding of COPD pathogenesis, 
although the relationships between airway inflammation, 
smoking status, and physiological disease appear complex.
There are some data available from more limited studies 
that support our findings. Willemse et al compared current 
smokers with COPD using sputum and airway wall biopsy 
cell profiles to current smokers without COPD and then 
conducted a smoking cessation study in both participant 
populations.25,26 Established COPD was associated with 
increased sputum neutrophils and eosinophilic cationic 
protein (ECP) levels, but there were no changes within the 
airway wall that discriminated smokers with COPD from 
those without, although smoking per se was related to an 
increase in airway biopsy macrophages. Interestingly, fol-
lowing one year of smoking cessation there were significant 
increases in sputum neutrophils, as well as IL-8 and ECP 
levels – but only in those participants with COPD, whereas 
inflammatory cell counts and cytokine levels were sig-
nificantly reduced in the smokers without COPD who had 
successfully quit. Once again, there were no changes in cell 
Table 6 Significant correlations between smoking and lung function 
and airway inflammation in COPD current and ex-smokers
Smoking pack-years/
cigarettes smoked  
per day
r P value
Current  
smokers  
(n = 17)
Pre-BD FeV1,  
% predicted
-0.41/-0.57 0.10/0.02
Post-BD FeV1,  
% predicted
-0.58/-0.70 0.01/0.00
Pre-BD Fer -0.58/-0.51 0.01/0.04
Post-BD Fer -0.57/-0.30 0.02/0.24
Pre-BDFeF25-75%, 
% predicted
-0.52/-0.65 0.03/0.00
Post-BD  
FeF25-75%, L/sec
-0.54/-0.45 0.02/0.07
Post-BDFeF25-75%,  
% predicted
-0.65/-0.57 0.00/0.02
Pre-BD PeF,  
% predicted
-0.56/-0.56 0.02/0.02
BAL total cells,  
103/mL
-0.57/-0.55 0.02/0.02
BAL mast cells,  
103/mL
-0.55/-0.39 0.02/0.13
ex-smokers 
(n = 17)
sputum lymphocytes, % -0.60/-0.49 0.01/0.05
sputum lymphocytes,  
104/mL
-0.52/-0.58 0.04/0.02
sputum mast cells,  
104/mL
-0.46/-0.63 0.07/0.01
BAL macrophages, % 0.39/0.62 0.14/0.01
BAL macrophages,  
103/mL
0.45/0.58 0.07/0.02
BAL epithelial cells, % -0.50/-0.52 0.05/0.04
Biopsy CD8+ve  
cells/mm
-0.54/-0.13 0.03/0.6International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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profiles in bronchial biopsies and Willemse and colleagues 
concluded that airway wall remodeling may be the more 
important factor and also that the apparent increase in inflam-
mation could reflect an active repair process.26 Lapperre et al 
from the same research team used pooled data from several 
centres27 to undertake a cross-sectional comparison of airway 
biopsies in over a 100 participants with COPD and found 
increased CD3+ve, CD4+ve, and CD8+ve lymphocytes in 
short term quitters, but an increase in airway wall plasma 
cell and reduction in CD8+ve numbers in ex-smokers with 
longer durations of smoking cessation. Altogether, these 
studies are consistent with our findings that inflammation 
does not seem to reduce following smoking cessation in the 
setting of established COPD and indeed may worsen, but 
whether this is part of a repair process requires more inves-
tigation into which inflammatory changes within the three 
airway compartments are related to changes of remodeling 
within the airway wall.
Table 7 Significant correlations between sputum or BAL cells and lung function in COPD current and ex-smokers
r P value
Current smokers 
(n = 17)
Pre BD FVC, % predicted sputum macrophages, % 0.51 0.04
sputum macrophages, 104/mL 0.52 0.03
BAL total cells, 103/mL 0.52 0.03
BAL epithelial cells, % -0.50 0.04
BAL macrophages, 103/mL 0.53 0.03
Post BD FVC, % predicted sputum macrophages, 104/mL 0.57 0.02
BAL epithelial cells, % -0.48 0.05
BDr, % of baseline sputum macrophages, 104/mL -0.52 0.03
Pre BD PeF, L/sec sputum epithelial cells, % 
sputum epithelial cells, 104/mL
0.48 
0.60
0.05 
0.01
ex-smokers 
(n = 17)
BDr, % of baseline BAL total cells, 103/mL -0.65 0.01
BAL lymphocytes, 103/mL -0.58 0.01
BDr, % of predicted sputum eosinophils, % -0.50 0.05
BAL total cells, 103/mL -0.71 0.002
BAL lymphocytes, 103/mL -0.48 0.05
Pre BD PeF, % predicted sputum macrophages, % -0.57 0.02
BAL total cells, 103/mL 0.59 0.02
Pre BD PeF, % predicted BAL total cells, 103/mL 0.50 0.05
Table 8 Significant correlations between lung function and biopsy cells in COPD current and ex-smokers
r P value
Current smokers 
(n = 17)
neutrophil/mm Pre BD FeV1, L 0.58 0.02
Post BD FeV1, L 0.65 0.01
Pre BD FVC, L 0.57 0.02
Pre BD FVC, % predicted 0.52 0.04
Post BD FVC, L 0.56 0.02
Post BD FVC, % predicted 0.58 0.02
Lymphocyte CD4/mm Post BD FeV1, L 0.63 0.01
Post BD FVC, L 0.58 0.01
Pre BD FeF 25%–75%, L/sec 0.59 0.01
Pre BD FeF 25%–75%, % predicted 0.49 0.05
Post BD FeF 25%–75%, L/sec 0.50 0.04
Post BD PeF, L/sec 0.49 0.04
ex-smokers 
(n = 17)
Lymphocyte CD4/mm Pre BD FeV1, L 0.60 0.01
Post BD FeV1, L 0.66 0.01
Post BD FeF 25%–75%, L/sec 0.51 0.04
Mast cell/mm Pre BD FeV1, % predicted 0.55 0.02
Post BD FeV1, % predicted 0.53 0.03
Pre BD FeF 25%–75%, L/sec 0.52 0.03
Pre BD FeF 25%–75%, % predicted 0.55 0.02
Post BD FeF 25%–75%, L/sec 0.51 0.04
Post BD PeF, % predicted 0.58 0.01International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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A further potential explanation for some of the differences 
seen in COPD between current and ex-smokers, such as a 
difference in BAL macrophages, may be alterations in the 
balance between inflammatory cell recruitment, apoptosis, 
and apoptotic cell clearance induced by smoking.28,29 On the 
other hand, the increase in mast cells in sputum and eosino-
phils in BAL in current smokers compared to ex-smokers may 
reflect an “allergic” response to cigarette smoke components, 
as has been suggested previously and this could be consistent 
with the higher sputum ECP levels in COPD current smokers 
observed in Willemse et al’s study or in the general push of 
active smoking to produce higher systemic IgE levels.30,31
The lack of relationship between cell profiles in sputum, 
BAL, and biopsies indicates that the effects of smoking or 
smoking cessation are different depending on which airway 
compartment one studies, suggesting that to get a truly holis-
tic view of the effects of smoking, one needs to sample all 
compartments. The other important message is that sputum 
cell profiles do not reflect airway pathology in either more 
distal airways (sampled by BAL), or in more central airway 
walls, which cautions against overinterpretation of sputum 
indices when commenting on airway pathology in COPD.
In summary, in this three compartment airway study we 
compared inflammatory cell profiles in current and ex-smokers 
with COPD and demonstrated that there is a complex interplay 
between smoking and airway inflammation in COPD, which var-
ies depending on which airway compartment is being assessed. 
Ex-smokers with COPD have persisting airway inflammation, 
which differs qualitatively and quantitatively from current 
smokers. Prospective studies of smoking cessation now need 
to consider the relationship between inflammation and airway 
remodeling/repair, which may influence these cell profiles.
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